Abstract Number: 577 • 2015 ACR/ARHP Annual Meeting
Use of Subcutaneous MTX Does Not Prolong the Use of Traditional DMARD in Multi-DMARD Regimens and Has Insignificant Differences in Liver Enzymes Abnormalities When Compared with Oral MTX in Patients with Rheumatoid Arthritis: A Veteran Affairs Administrative Database Study
Background/Purpose: Our previous analyses using the national administrative database from Veteran Health Administration showed that RA patient who were switched from oral to subcutaneous MTX…Abstract Number: 578 • 2015 ACR/ARHP Annual Meeting
Study of the Production of Antinuclear Antibodies and Anti-Ds DNA Antibodies in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Background/Purpose: The production of autoantibodies, such as anti-nuclear antibodies (ANA) and anti-ds DNA antibodies (anti-DNA), is commonly observed in patients who have been treated with…Abstract Number: 579 • 2015 ACR/ARHP Annual Meeting
Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduction of bone mineral density (BMD) and increased risk of peripheral and axial fractures. Methotrexate is the first-line…Abstract Number: 580 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
Background/Purpose: It is a well-known fact the decline of life expectancy in Rheumatoid Arthritis (RA) being the increased mortality in these patients a constant concern…Abstract Number: 581 • 2015 ACR/ARHP Annual Meeting
Optimization of Treatment Intervals of Tocilizumab and Golimumab By Measuring Serum Trough Levels in Rheumatoid Arthritis Patients
Background/Purpose: Biologic agents have dramatically improved the outcome of rheumatoid arthritis (RA) patients. However, the administration dose and treatment intervals of these agents are usually…Abstract Number: 582 • 2015 ACR/ARHP Annual Meeting
Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Background/Purpose: Last years, biological dose tapering in patients with inflammatory diseases has become a routine clinical practice. Since 2011 we are applying a dose reduction…Abstract Number: 583 • 2015 ACR/ARHP Annual Meeting
A Serological Biomarker of Active MMP3, but Total MMP3, Can Early Assess Treatment Efficacy and Differentiate Doses of Tocilizumab and an Early Change in Active MMP3, but Not Total MMP3, Is Associated with Radiographic Change at 1 Year
Background/Purpose: Protease activity, especially MMP3, is known to be increased with arthritis, such as rheumatoid arthritis. MMP3 is mainly expressed by fibroblasts; a key cell…Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…Abstract Number: 585 • 2015 ACR/ARHP Annual Meeting
Outcomes after Discontinuing Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis: 2 Years of ‘post-Golimumab’ after Completion of the 5-Year Extension Study in Korea
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have helped patients achieve remarkable outcomes as in improving synovitis and halting structural damages in severe cases of rheumatoid…Abstract Number: 586 • 2015 ACR/ARHP Annual Meeting
Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis
Background/Purpose: Anti-citrullinated protein antibody (ACPA) has been an important marker in diagnosing rheumatoid arthritis (RA). Its predictive value remains unclear; therefore, here we investigated whether…Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…Abstract Number: 588 • 2015 ACR/ARHP Annual Meeting
Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Background/Purpose: Tocilizumab (TCZ) is clinically effective against rheumatoid arthritis (RA) and over 50% of RA patients who had completed 5 years of TCZ treatment maintained…Abstract Number: 589 • 2015 ACR/ARHP Annual Meeting
Adalimumab Concentration at 16 Weeks of Treatment Is Associated with Treatment Discontinuation within One Year
Background/Purpose: Anti-drug antibodies (ADAb) in patients treated with adalimumab have been associated with decreased adalimumab concentrations and loss of clinical response, and therefore treatment discontinuation.…Abstract Number: 590 • 2015 ACR/ARHP Annual Meeting
Expression Levels of Selected Genes May Predict Response to TNF Alpha Blockers or Rituximab in the Individual Rheumatoid Arthritis Patient
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a variety of therapeutic options however tools to predict individual patients' response are limited. The purpose of this…Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…
ACR Meeting Abstracts